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Oxidation of various heterocyclyl N-acylhydrazones
3a-j with, iodobenzene diacetate (IBD) in di-
chloromethane provides a facile method for the synthe-
sis ofheterocyclyl-l ,3,4-oxadiazoles 4a-j.
Hypervalent iodine (III) reagents have generated
considerable interest in the recent years due to
their applications in the synthesis of heterocyclic
compounds 1.3. In continuation of our efforts in de-
veloping I(III) mediated methods for the synthesis
of heterocyclic compounds" we have focussed our
attention to the synthesis of heterocyclyl-l,3,4-
oxadiazoles. There are several methods reported in
the literature for the synthesis of oxadiazoles from
acylhydrazones, which include oxidation with lead
tetraacetate (LTA)5 or electrochemical oxidation of
N-acylhydrazones of aldehydest.The iodobenzene
diacetate (IBD) has also been employed for the
synthesis of oxadiazoles from simple alkyl and
phenyl acylhydrazones",
. Our ongoing interest in the development of sim-
pler hypervalent iodine mediated methodologies in
heterocyclic synthesis', coupled with the signifi-
cant biological importance of oxadiazoles in medi-
cine and agrochernicals'"!' prompted us to under-
take the oxidation of the acylhydrazones of hetero-
cyclic acid hydrazides. We report in this note the
synthesis of heterocyclyl-l,3,4-oxadiazoles 4a-j
using IBD as an oxidizing reagent (cf. Scheme I).
Heterocyclyl N-acylhydrazones 3a-j were pre-
pared by the condensation of appropriate aldehy-
des with heterocyclyl acylhydrazines (Table I).
The oxidative cyclization of aldehyde N-
acylhydrazones 3a-j to 4a-j was effected by using
Note
MaOH
Het-CONHNH 2 + Ar-CHO ---' •• Hat-CONHN=CH-Ar






IBD and the results are summarized in Table II. It
is to be noted that when Het is 4-(5-methyl-l-
phenyl-pyrazolyl), the reaction is completed within
10 minutes at room temperature using one equiva-
lent of IBD, whereas when Het is 2-benzothiazolyl,
the reaction requires 30 minutes at reflux tem-
perature, and two equivalents of IBD. A plausible
mechanism for the conversion of 3 to 4 is outlined
in Scheme II.
The intermediates 5 and 6 are suggested on the
basis of oxidation of Schiff bases by IBD12, and
oxidative cyclisation of N-acylhydrazone7• In con-
clusion we find that IBD is a reagent of choice for
the synthesis of heterocyclyl substituted 1,3,4-
oxadiazoles, as compared to other reported meth-
ods which involve the use of toxic reagents like
LTA5. In addition, this IBD mediated synthesis of
1,3,4-oxadiazoles is very facile and quick.
Experimental Section
All melting points are uncorrected. IH NMR
spectra in CDCl3 were recorded on a 300 MHz
spectrometer USing TMS as an internal standard,
IR spectra in KBr on a Perkin-Elmer 237B spec-
trometer, and mass spectra on a Hewlett-Packard
GCIMS-5985 instrument. Compounds 1 were pre-
pared through the reported procedure'".
Heterocyclyl acylhydrazones 3a-j: General
Procedure. To an ethanolic solution of 1 (0.01
mole) was added corresponding benzaldehyde
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(0.011 mole) and the solution was refluxed for 1-2
hr. The solvent was evaporated in vacuo to half its
volume and cooled to room temperature. The solid
obtained was filtered and washed with ethanol.
The physical data of3a-j are listed in Table 1.
N-(2- Benzothiazoloyl) -N -benzylldenehydra-
zine 3a : 'HNMR : 8 7.22-7.25 (m, 2H, ArH),
7.46-7.58 (m, 2H, benzothiazolyl Cs-H and C6-H),
7.68:'7.72 (d, 3H, ArH), 7.98-8.00 (dd, IH, ben-
zothiazolyl C4-H), 8.05-8.10 (dd, IH, benzothia-
zolyl C7-H), 8.31 (s, IH, -N=CH), 1O.39(s, 1H;
NH exchangeable with D20) ; IR (KBr/cm-') :
3210(NH), 1659(C=O), 1604, 1571(Ar) (Found:
C, 64.01 ; H, 3.82; N, 15.02. CIsHllN30S requires
C, 64.06; H, 3.91 ; N, 14.95%).
N-(2-BenzothiazoJoyJ) -N~(4-methyJbenzyli-














CH3), 7.21-7.26 (m, 2H, ArH), 7.48-7.59 (m, 2H,
benzothiazolyl Cs-H and C6-H), 7.69-7.72 (d, 2H,
ArH), 7.97-8.00 (dd, 1H, benzothiazolyl C.-H),
8.06-8.09 (dd, IH, benzothiazolyl C7-H), 8.32 (s,
IH, -N=CH), 10.41(s, 1H, NH exchangeable with
D20) (Found : C, 65.13; H, 4.13; N, 14.19.
CI6H13N30S requires C, 65.08; H, 4.41; N,
14.33%).
N-(2- Benzothiazoloyl)-N' -(4-methoxybenzyli-
dene)hydrazine 3d: 'HNMR: 8 3.86 (s, 3H,
-OCH3), 6.94-6.98 (dd, 2H, ArH), 7.50-7.61 (m,
2H, benzothiazolyl Cs-H and C6-H), 7.75-7.80 (d,
2H, ArH), 7.99-8.11 (m, 2H, benzothiazolyl C4-H
and C7-H), 8.30 (s, IH, N=CH), 10.33 (s, 1H, NH
exchangeable with D20) (Found: C, 61.72 ; H,
3.97; N, 13.65. C'6HI3N302Srequires C, 61.74 ; H,
4.18; N, 13.51%).
N-(5-Methyl-l-phenyl-4-pyrazoloyl)- N<ben-
zylidenehydrazine 3f : 'HNMR : 8 2.64 (s, 3H,
pyrazolyl CS-CH3), 7.39-7.71 (m, lOH, ArH), 7.88
(s, IH, pyrazolyl C3-H), 8.54 (s, 1H, N=CH), 9.41
(brs, 1H, NH, exchangeable with D20) (Found: C,
70.88 ; H, 4.92 ; N, 18.12. C,sH'6N40 requires C,
71.05; H, 5.26; N, 18.42%).
N-(5-Methyl-l-phenyl-4-pyrazoloyl)- N~( 4-
methylbenzylidene)hydrazine 3g: 'HNMR:
8 2.37 (s, 3H, CH3), 2.64 (s, 3H, pyrazolyl Cs-
CH3), 7.19-7.88 (m, 9H, ArH), 7.88 (s,IH, pyra-
zolyl C3-H), 8.55 (s, IH, N=CH), 9.75 (brs, IH,
NH exchangeable with D20) (Found: C, 71.52 ; H,
5.39 ; N, 17.48. C'9H,sN40 requires C, 71.69; H,
5.66; N, 17.61%).
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Table II-Physical data of compounds 4a-j
Compd Het Ar m.p.(Iit13a.m.p.) Yield
°C %
4a* O:~ Ph 176-77(177) 65% s)l.
O:N4b % I s)l. 4-CH3C6H. 185-86 76
O:N4c % I s)l. 4-CIC6H. 178(178) 66
4d 4-0MeC6H. 180-81(180) 72
O:N4e % I s)l. 4-N02C6H. 230-31(234) 60
4f UN_N Ph 174 71CHr-Y
4g UN-N 4-CH3C6H. 146 73CHr-Y
4h UN-N 4-CIC6H. 199 68CHr-Y
4i UN_N 4-0MeC6H. 155 78CHr-Y
4j UN-N 4-N02C6H4 218 72CHr-Y
*4a; IR (KBr/cm-I): 1560,1545 (Ar); Mass: mlz (M+I, CI); 280 (100), 279 (61.07), 253 (0.60),250 (4.20), 240 (1.10), 238
(0.50),237 (2.39), 224 (2.82), 223 (55.83).
Moreover, IH NMR spectra of 3 revealed the presence of exchangeable NH proton, which were absent in case of 4.The char-
acteristic O=O and N-H stretching of3 were absent in IR spectra of 4.
N-(5-Methyl-l-phenyl-4-pyrazoloyl)- N~(4-
chlorobenzylidene)hydrazine 3h: lHNMR: 82.34
(s, 3H, pyrazolyl CS-CH3), 7.36-7.85 (m, 9H, ArH),
7.83 (s, 1H, pyrazolyl C3-H), 8.49 (s, 1H, N=CH),
9.26 (brs, 1H, NH exchangeable with DzO); Mass:
m/z 338 (M++2) (Found: C, 63.71; H, 4.18; N,




s 2.64 (s, 3H, pyrazolyl CS-CH3), 3.85 (s, 3H,
OCH3), 7.10-7.66 (m, 9H, ArH), 7.79 (s, 1H, pyra-
zolyl C3-H), 8.53(s, 1H, N=CH), 8.97(s, 1H, NH
exchangeable with DzO) (Found: C, 68.22 ; H,
5.11 ; N, 16.44. Cl9H1SN402requires C, 68.26 ; H,
5.38; N, 16.76%).
N-(5-Methyl-l-phenyl-4-pyrazoloyl)- N ~(4-
nitrobenzylidene)hydrazine 3j: lHNMR: 0 3.00
(s, 3H, pyrazolyl CS-CH3), 7.45-8.25 (m, 10H, ArH
and pyrazolyl C3-H), 8.48 (lH, s, N=CH), 11.61
(lH, s, NH, exchangeable with D20) (Found: C,
61.65 ; H, 4.12 ; N, 19.92. CisH1SNs03 requires C,
61.89; H, 4.29 ; N, 20.04%).
Heterocyclyl-l,3,4-oxadiazoles 4a-j : General
Procedure. To a stirred solution of 3 (l0 mmoles)
in dichloromethane (10 mL) was added IBD (10
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-noles, when Het = 5-methyl-l-phenyl-4-yl and
20 mmo1es, when Het = 2-benzothiazo1y1)and the
mixture was stirred at room temperature in the case
of former and refluxed for 10 to 30 min. on a wa-
ter-bath in the case of latter. Concentration of the
mixture in vacuo, followed by recrystallization
from ethanol or purification by column chromatog-
raphy on silica gel using petroleum ether-ethyl
acetate as an eluant gave pure products. Physical
data of 4a-j are listed in Table II.
2-Benzothiazolyl-5-( 4-tolyl)-1,3, 4-oxadiazole
4b:,IHNMR : 8 2.46 (s, 3H, CH)), 7.35-7.55 (d,
2H, ArH), 7.58-7.63 (m, 2H, benzothiazolyl), 8.00-
9.27 (m, 4H, benzothiazolyl and ArH) (Found: C,
65.51 ; H, 3.48 ; N, 14.22. CI6HIIN)OSrequires C,
65.53 ; H, 3.75 ; N, 14.33%).
2-(5-Methyl-l-phenyl-4-pyrazolyl)- 5-phenyl-
1,3,4-oxadiazole 4f : IHNMR : 8 2.74 (s, 3H,
pyrazolyl C)-CH)), 7.47-8.14 (m, 10H, ArH), 8.18 2
(s, IH, pyrazoly1 C)-H) (Found: C, 71.42 ; H, 4.54
; N, 18.32. CIsHI4N40requires C, 7l.52 ; H, 4.63 ;
N,18.54%).
2-(5-Methyl-l-phenyl-4-pyrazolyl)- 5-(4-tolyl)- 3
1,3,4-oxadiazole 4g: IHNMR: 8 2.44 (s, 3H, CH)),
2.73 (s, 3H, pyrazolyl Cs-CH)), 7.26-7.99 (m, 9H, 4
ArH), 8.17 (s, IH, pyrazolyl C)-H) ; Mass: m/z
316 (M+) (Found: C, 7l.98 ; H, 4.91 ; N, 17.46.
C1JII6N40 requires C, 72.15 ; H, 5.06 ; N,
17.72%). 5
2-(5-Methyl-l-phenyl-4-pyrazolyl)- 5-(4-chlo- '
rophenyl)-1,3,4-oxadiazole 4h : IHNMR : 8 2.74
6(s, 3H, pyrazoly1Cs-CH3),7.45-8.09 (m, 9H, ArH), 7
8.16 (s, IH, pyrazo1e C)-H) ; Mass: m/z 336 (M+) 8
(Found : C, 64.12 ; H, 3.71 ; N, 16.57.
C1sH13CIN40requires C, 64.28 ; H, 3.86 ; N, 9
16.66%).
2-(5-Methyl-l-phenyl-4-pyrazolyl)- 5-(4-ani-
syl)-1,3,4-oxadiazole 4i : IHNMR : 8 2.73 (s, 3H, II
pyrazolyl Cs-CH)), 3.89 (s, 3H, OCH)), 7.01-8.07
(m, 9H, ArH), 8.16 (s, IH, pyrazoly1 C)-H)
(Found: C, 68.32 ; H, 4.52 ; N, 16.78. CI9HI6NP
requires C, 68.67; H, 4.81 ; N, 16.86%).
* Compounds 4a-e are reported in the literature except:
4b and 4f-j which were synthesized for the first time.
2-(5-Methyl-l-phenyl-4-pyrazolyl)-5-( 4-nitro-
phenyl)-1,3,4-oxadiazole 4j: IHNMR:
(CDC13+DMSO);8 2.76 (s, 3H, pyrazoly1 Cs-CH)),
7.45-8.42 (m, 10H, ArH and pyrazolyl C3-H)
(Found :C, 62.02 ; H, 3.63 ; N, 20.34. CIsH13Ns03
requires C, 62.24 ; H, 3.74 ; N, 20.17%).
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